Discodermolide

Jump to: navigation, search
Template:Chembox E number
Discodermolide
IUPAC name (+)-Discodermolide
Identifiers
3D model (JSmol)
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
Properties
C33H55NO8
Molar mass 593.79 g/mol
Melting point
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)

Infobox disclaimer and references

WikiDoc Resources for Discodermolide

Articles

Most recent articles on Discodermolide

Most cited articles on Discodermolide

Review articles on Discodermolide

Articles on Discodermolide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Discodermolide

Images of Discodermolide

Photos of Discodermolide

Podcasts & MP3s on Discodermolide

Videos on Discodermolide

Evidence Based Medicine

Cochrane Collaboration on Discodermolide

Bandolier on Discodermolide

TRIP on Discodermolide

Clinical Trials

Ongoing Trials on Discodermolide at Clinical Trials.gov

Trial results on Discodermolide

Clinical Trials on Discodermolide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Discodermolide

NICE Guidance on Discodermolide

NHS PRODIGY Guidance

FDA on Discodermolide

CDC on Discodermolide

Books

Books on Discodermolide

News

Discodermolide in the news

Be alerted to news on Discodermolide

News trends on Discodermolide

Commentary

Blogs on Discodermolide

Definitions

Definitions of Discodermolide

Patient Resources / Community

Patient resources on Discodermolide

Discussion groups on Discodermolide

Patient Handouts on Discodermolide

Directions to Hospitals Treating Discodermolide

Risk calculators and risk factors for Discodermolide

Healthcare Provider Resources

Symptoms of Discodermolide

Causes & Risk Factors for Discodermolide

Diagnostic studies for Discodermolide

Treatment of Discodermolide

Continuing Medical Education (CME)

CME Programs on Discodermolide

International

Discodermolide en Espanol

Discodermolide en Francais

Business

Discodermolide in the Marketplace

Patents on Discodermolide

Experimental / Informatics

List of terms related to Discodermolide


Overview

(+)-Discodermolide is a recently discovered polyketide natural product found to be a potent inhibitor of tumor cell growth. The molecule's carbon skeleton is made up of eight polypropionate and four acetate units with 13 stereocenters.

History

Discodermolide was first isolated in 1990 from the Caribbean marine sponge Discodermia dissoluta by chemist Dr. Sarath Gunasekera and biologist Dr. Ross Longley, scientists at the Harbor Branch Oceanographic Institution.[1][2][3] The sponge contained 0.002% of discodermolide (7 mg/434 g of sponge). Since the compound is light-sensitive, the sponge must be harvested at a minimum depth of 33 meters. Discodermolide was initially found to have immunosuppressive and antifungal activities.

Mechanism of action

Discodermolide has been shown to inhibit the proliferation of human cells by arresting the cell cycle in G2- and M-phase. It hyper-stabilizes microtubules, especially prevalent during cell division, and competes with paclitaxel for microtubule binding, but with higher affinity.[4][5][6] Over a variety of cell lines, activity has been measured at IC50 = 3-80 nM.

Hyper-stabilization of the mitotic spindle causes cell cycle arrest and cell death by apoptosis.

Discodermolide is effective in paclitaxel- and epothilone-resistant cancer cells.[7]

Total syntheses

Several total syntheses have been published to date by Schreiber[8][9], Smith[10][11][12], Paterson[13], Marshall[14], and Myles[15]. A review of the various synthetic approaches has also been published.[16]

Clinical development

The Harbor Branch Oceanographic Institution licensed (+)-discodermolide to Novartis, which began a phase 1 clinical trial in 2004. Patient accrual was halted due to drug toxicitiy.[17] The Amos B. Smith's research group (in collaboration with Kosan Biosciences) has a preclinical drug development program ongoing.[18]

The compound supply necessary for complete clinical trials cannot be met by harvesting, isolation, and purification. As of 2005, attempts at synthesis or semi-synthesis by fermentation have proven unsuccessful. As a result, all discodermolide used in preclinical studies and clinical trials has come from large-scale total synthesis.[19][20]

See also

References

  1. ^ Gunasekera, S. P.; Gunasekera, M.; Longley, R. E.; Schulte, G. K. J. Org. Chem. 1990, 55, 4912-4915. (doi:10.1021/jo00303a029)
  2. ^ Gunasekera, S. P.; Pomponi, S. A.; Longley, R. E.; U.S. Patent 5,840,750, November 24, 1998.
  3. ^ Gunasekera, S. P.; Paul, G. K.; Longley, R. E.; Isbrucker, R. A.; Pomponi, S. A. J. Nat. Prod. 2002, 65, 1643.
  4. ^ Ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M., Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Biochemistry 1996, 35, 243-250. (Abstract)
  5. ^ Hung, D. T.; Chen, J.; Schreiber, S. L. Chem Biol. 1996, 3, 287-293. (Abstract)
  6. ^ Klein, L. E.; Freeze, B. S.; Smith, A. B.; Horwitz, S. B. Cell Cycle 2005, 4, 501-507. (Article)
  7. ^ Jordan, M. A. Curr. Med. Chem.: Anti-Cancer Agents 2002, 2, 1.
  8. ^ Nerenberg, J. B.; Hung, D. T.; Somers, P. K.; Schreiber, S. L. J. Am. Chem. Soc. 1993, 115, 12621-12622. (doi:10.1021/ja00079a066)
  9. ^ Hung, D. T.; Nerenberg, J. B.; Schreiber, S. L. J. Am. Chem. Soc. 1996, 118, 11054-11080. (doi:10.1021/ja961374o)
  10. ^ Smith, A. B. III. et al. J. Am. Chem. Soc. 1995, 117, 12011-12012. (doi:10.1021/ja00153a030)
  11. ^ Smith, A. B.; Beauchamp, T. J.; LaMarche, M. J.; Kaufman, M. D.; Qiu, Y.; Arimoto, H.; Jones, D. R.; Kobayashi, K. J. Am. Chem. Soc. 2000, 122, 8654-8664. (Article)
  12. ^ Smith, A. B.; Freeze, B. S.; Xian, M.; Hirose, T. Org. Lett. 2005, 7, 1825-1828.
  13. ^ Paterson, I.; Florence, G. J.; Gerlach, K.; Scott, J. P. Angew. Chem. Int. Ed. Engl. 2000, 39, 377. (Article)
  14. ^ Marshall, J. A.; Johns, B. A. J. Org. Chem. 1998, 63, 7885-7892. (doi:10.1021/jo9811423)
  15. ^ Harried, S. S.; Yang, G.; Strawn, M. A.; Myles, D. C. J. Org. Chem. 1997, 62, 6098-6099. (doi:10.1021/jo9708093)
  16. ^ Paterson, I.; Florence, G. J. Eur. J. Org. Chem. 2003, 2193.
  17. ^ A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. 2004 ASCO Annual Meeting (Abstract and Presentation Slides)
  18. ^ Amos B. Smith, III Current Research Projects
  19. ^ Mickel, S. J. et al. Org. Process Res. Dev. 2004, 8, 92, 101, 107, 113 and 122.
  20. ^ Wulff research group (PDF)

External links

he:דיסקודרמוליד



Linked-in.jpg